Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from University of Manchester yield new information about cancer vaccines
June 25th, 2008
" The human 5T4 ( h5T4) oncofoetal antigen is expressed by a wide variety of human carcinomas including colorectal, ovarian, gastric and renal, but rarely on normal tissues. Its restricted expression on tumour tissues as well as its association with tumour progression and bad prognosis has driven the development of a MVA-based vaccine (TroVax) which has been tested in several early phase clinical trials and these studies have led to the start of a phase III trial in renal cell carcinoma patients," scientists writing in the journal Cancer Immunology Immunotherapy report. "We have recently shown that CD8(+) T cells recognizing h5T4 can be generated in the absence...
Source: Vaccine Weekly (2008-06-25)
|
